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Background. The relationship between cannabis use and cognitive functioning in patients with psychosis has yielded
contradictory ﬁndings. In individuals at genetic high risk for psychosis, information is sparse. The aim of this study
was to assess the association between recency and frequency of cannabis use and cognitive functioning in patients
with psychosis and their unaﬀected siblings.
Method. We conducted a cross-sectional study in 956 patients with non-aﬀective psychosis, 953 unaﬀected siblings,
and 554 control subjects. Participants completed a cognitive test battery including assessments of verbal learning, set
shifting, sustained attention, processing speed, working memory, acquired knowledge, reasoning and problem
solving and social cognition. Cannabis use was assessed by urinalysis and by the Composite International Diagnostic
Interview. Using random-eﬀect regression models the main eﬀects of cannabis (recency and frequency) and the
interaction with status (patient, sibling, control) on cognitive functioning were assessed.
Results. Current cannabis use was associated with poorer performance on immediate verbal learning, processing
speed and working memory (Cohen’s d x0.20 to x0.33, p<0.005). Lifetime cannabis use was associated with better
performance on acquired knowledge, facial aﬀect recognition and face identity recognition (Cohen’s d+0.17 to
+0.33, p<0.005). There was no signiﬁcant interaction between cannabis and status on cognitive functioning.
Conclusions. Lifetime cannabis-using individuals might constitute a subgroup with a higher cognitive potential. The
residual eﬀects of cannabis may impair short-term memory and processing speed.
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Introduction
Cognitive impairment is recognized as a core feature
of schizophrenia (Green, 1996 ; Palmer et al. 2009).
Mild cognitive alterations are also observed in unaﬀec-
ted relatives of patients who are at increased risk to
develop a psychotic disorder (Snitz et al. 2006). In both
patients with psychosis and their unaﬀected siblings,
cannabis use is more prevalent than in the general
population (Barnes et al. 2006 ; Smith et al. 2008). In
patients with psychosis, cannabis use has been as-
sociated with worse disease outcome (Linszen et al.
1994). In unaﬀected siblings the psychotomimetic ef-
fect of cannabis is increased compared with control
subjects, suggesting that familial liability to psychosis
is associated with sensitivity to cannabis [Genetic Risk
and Outcome of Psychosis (GROUP) Investigators,
2011 ; van Winkel, 2011]. Whether cannabis use is also
associated with cognitive alterations in patients with
psychosis and their unaﬀected relatives is, however,
still a matter of debate.
Acute administration of the major psychoactive
component in cannabis (n9-tetrahydrocannabinol ;
THC) has been shown to cause impaired attention and
memory in schizophrenia patients and their unaﬀec-
ted siblings (D’Souza et al. 2005 ; Henquet et al. 2006).
These impairments in patients and siblings were lar-
ger compared with those in healthy controls, suggest-
ing an increased sensitivity to the adverse cognitive
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eﬀects of acute cannabinoid administration. On the
contrary, better cognitive functioning has also been
reported in cannabis-using patients compared with
non-using patients on tasks of planning and reason-
ing, visual memory, processing speed, global cog-
nition and working memory (Coulston et al. 2007a ;
Potvin et al. 2008 ; Loberg & Hugdahl, 2009 ; Yu¨cel et al.
2010).
This superior cognitive functioning in cannabis-
using patients seems counterintuitive given the del-
eterious cognitive eﬀects that have been reported in
cannabis-using control subjects (Solowij & Michie,
2007 ; Morrison et al. 2009). Two hypotheses attempt
to explain these results. First, it has been suggested
that cannabis improves cognition, either by counter-
acting a putative neurotoxic process related to
schizophrenia, or by stimulating prefrontal neuro-
transmission (Verrico et al. 2003 ; Jockers-Scherubl et al.
2007 ; Coulston et al. 2007a, b ; Potvin et al. 2008 ; Cohen
et al. 2008). Second, it has been suggested that causality
is the other way round. In this view, patients with
psychotic disorder and lifetime cannabis use may
form a subgroup with a relatively lower genetic vul-
nerability for psychosis and better pre-morbid func-
tioning compared with patients who have never used
cannabis (Schnell et al. 2009 ; de la Serna et al. 2010 ;
Yu¨cel et al. 2010).
Elucidating the association between cannabis use
and cognitive functioning in patients and individuals
at genetic high risk for psychosis is of both theoretical
and clinical relevance (Loberg & Hugdahl, 2009).
Whilst spared cognitive functioning through cannabis
use would be relevant for the development of
cognitive-enhancing medication, a further cognitive
decline associated with cannabis use should stimulate
development of interventions aiming at a reduction of
cannabis use.
It seems essential to account for the recency of can-
nabis use in studies on the association between can-
nabis and cognitive functioning, since contradictory
ﬁndings between acute administration and lifetime
cannabis use have been found (D’Souza et al. 2005 ;
Henquet et al. 2006 ; Coulston et al. 2007a ; Potvin et al.
2008 ; Loberg & Hugdahl, 2009 ; Yu¨cel et al. 2010). In
addition, the frequency of cannabis use should be ta-
ken into account in order to investigate dose–response
relationships (Coulston et al. 2007a). Thus, the aim of
the present study was to investigate if cognitive per-
formance diﬀers between cannabis users and non-
users depending on the recency and frequency of use.
Moreover, we wanted to investigate whether these
associations are diﬀerent in patients with non-aﬀective
psychosis, their unaﬀected siblings and control sub-
jects. Our ﬁrst hypothesis was that current cannabis
use would be associated with worse cognitive
functioning in the three status groups (patient, sibling,
control), and that this association would be stronger
with increasing frequency of use over the past year.
Our second hypothesis was that there would be an
interaction between status and cannabis in lifetime
users. We expected lifetime cannabis use to be associ-
ated with better cognitive functioning in patients as
suggested by Yu¨cel et al. (2010), while we expected no
such association in siblings and controls.
Method
Study design and population
Data pertain to baseline measures of a longitudinal
study (GROUP) in the Netherlands and Belgium. In
selected representative geographical areas, patients
were identiﬁed through clinicians working in regional
psychotic disorder services whose caseloads were
screened for inclusion criteria. Subsequently, a group
of patients presenting consecutively at these services
as either out-patients or in-patients were recruited for
the study. Controls were selected through a system of
random mailings to addresses in the catchment areas
of the cases.
Inclusion criteria for patients, siblings, and controls
were : (1) age range of 16–50 years and (2) good com-
mand of the Dutch language. Patients had to meet
Diagnostic and Statistical Manual of Mental Disorders,
Fourth Edition, Text Revision (DSM-IV-TR) criteria for
a non-aﬀective psychotic disorder (APA, 2000) which
was assessed with the Comprehensive Assessment
of Symptoms and History interview (Andreasen et al.
1992) or the Schedules for Clinical Assessment for
Neuropsychiatry version 2.1 (Wing et al. 1990).
Exclusion criteria for healthy controls were a history of
psychotic disorder or a ﬁrst-degree family member
with a history of psychotic disorder.
The study protocol was approved centrally by the
Ethical Review Board of the University Medical Center
Utrecht and subsequently by local review boards of
each participating institute. All of the subjects gave
written informed consent in accordance with the
committee’s guidelines.
Substance use and clinical symptoms
Substance use was assessed with a short version of the
Composite International Diagnostic Interview (CIDI ;
WHO, 1990) sections B (tobacco use), J (alcohol use)
and L (substance use), and with urinalysis. Urine
was screened for the presence of THC with a cut oﬀ
of 50 ng/ml, in order to infer a detection window of
1 month. Cannabis recency was categorized as current
(urinalysis positive for THC), lifetime (urinalysis
706 J. H. Meijer et al.
negative and cannabis use ﬁve or more times lifetime
based on the CIDI), and never (urinalysis negative and
cannabis use less than ﬁve times lifetime based on the
CIDI). Although this latter group may have included
subjects who had limited experience with cannabis, for
simplicity this group is referred to as ‘never-users ’.
Cannabis frequency over the past year was categor-
ized as daily, weekly, or less than weekly, based on the
CIDI. Severity of positive and negative symptoms in
patients was rated with the Positive and Negative
Syndrome Scale (PANSS) with total scores for positive,
negative and general symptoms (Kay et al. 1987).
Cognitive assessment
The cognitive assessment took between 90 and
120 min. Subjects were administered 10 cognitive tasks
that yielded 13 outcome parameters which were used
as dependent variables in the analyses. Verbal learn-
ing was assessed using the Word Learning Task
(Brand & Jolles, 1985), with outcome parameters of
immediate recall (15-word list, three learning trials)
and retention rate after 20 min. Set shifting ability was
assessed using the Response Shifting Task (RST), a
modiﬁed version of the Competing Programs Task
(Bilder et al. 1992 ; Nolan et al. 2004), with outcome
parameters of reaction time and accuracy. Sustained
visual attention and vigilance were assessed using
the Continuous Performance Task-HQ (CPT A-X;
Nuechterlein & Dawson, 1984), with outcome para-
meters of reaction time and accuracy. The following
subtests of the Wechsler Adult Intelligence Scale-
Third Edition (WAIS-III ; Wechsler, 1997) were
assessed: Digit-Symbol Coding as a measure of pro-
cessing speed; Arithmetic as a measure of working
memory; Information as a measure of acquired
knowledge ; and Block Design as a measure of
reasoning and problem solving. The Degraded Facial
Aﬀect Recognition Task (Van ‘t Wout et al. 2004) was
used to assess recognition of neutral, happy, fearful
and angry emotions. The Benton Face Recognition
Task (Benton et al. 1983) was used to assess visuospa-
tial discrimination of unfamiliar faces. The Hinting
Task (Versmissen et al. 2008) was used to assess theory
of mind.
Statistical procedures
Diﬀerences in demographic and substance-use
characteristics between patients, siblings and controls
were tested with one-way analysis of variance or x2
tests. Diﬀerences in demographic and clinical charac-
teristics between cannabis-using patients (current and
lifetime combined) and never-using patients were
tested with independent t tests and x2 tests. These tests
were two-tailed with a signiﬁcance level of 0.05.
Furthermore, we used a three-step procedure to
assess the eﬀect of status (patient, sibling, control) and
cannabis recency (current, lifetime, never) on cognitive
functioning in the entire study sample (n=2463).
In the ﬁrst step we built a random-eﬀect regression
model for each cognitive functioning outcome.
Cognitive functioning was the dependent variable,
and status, cannabis recency and the statusrcannabis
recency interaction were independent variables as the
ﬁxed part of the model. To take dependency of the
data into account, because of intra-family correlation
between patients and siblings, family was entered as a
random factor with a random intercept into this re-
gression model. For the eﬀect of status, controls were
set as the reference category, against which patients
and siblings were compared. For the eﬀect of cannabis
recency, never-users were set as the reference cate-
gory, against which current and lifetime users were
compared. Additionally, regression analyses were re-
peated with current users as the reference category in
order to test signiﬁcant diﬀerences between current
and lifetime cannabis user groups.
A similar model was built for the 612 subjects who
had used cannabis in the preceding year, to assess the
eﬀect of cannabis frequency (daily, weekly, less) on
cognitive functioning. Frequency of use over the past
year was chosen over frequency of lifetime use, be-
cause self-report over a more recent period is less
likely to be subject to recollection bias. Moreover, any
frequency eﬀects of cannabis use may be confounded
by the time that has elapsed since the last use. While
this time-frame may be highly variable in lifetime
users (up to 10 years or more), in past-year users this is
limited. Cognitive functioning was the dependent
variable, and status, cannabis frequency and the
statusrcannabis frequency interaction were indepen-
dent variables as the ﬁxed part of the model. Family
was entered as a random factor with a random inter-
cept. Less than weekly users were set as a reference
category, against which the more frequent user groups
were compared.
In the second step we identiﬁed relevant con-
founders. Potential confounders that have been men-
tioned previously (Coulston et al. 2007b ; Potvin et al.
2008) were entered separately into the regression
models as covariates. A potential confounder was
considered a true confounder if adding the confounder
to the regression model changed the eﬀect estimates by
10% or more. The following covariates were tested:
age, gender, heavy alcohol use (>14 units weekly for
women and>20 units weekly for men), current nic-
otine use, a history of illicit substance use other than
cannabis over the past year (cocaine, amphetamines,
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XTC, opiates, inhalants, hallucinogens), and highest
parental education (ranging from 1=primary school to
8=university). In analyses with the Degraded Facial
Aﬀect Recognition task as the dependent variable,
the scores on the Benton Face Recognition Task were
added to the covariate set in order to diﬀerentiate facial
aﬀect recognition from non-emotional face-processing
skills.
In the third step the covariate set was added to the
ﬁxed part of the random-eﬀect regression models. If
the statusrcannabis recency (or cannabis frequency)
interaction term was not statistically signiﬁcant, it was
removed from the model and analyses were repeated
with the random-eﬀect model containing only the
main eﬀects and covariates.
Since the 13 cognitive outcome parameters came
from 10 cognitive tests, we divided the a level for the
statistical tests by 10. Adjustment for 13 comparisons
was considered too conservative, since the outcome
parameters derived from the same test were strongly
correlated (e.g. accuracy and reaction time as two
outcome parameters of the CPT A-X and the RST). Due
to the high power caused by the large n, eﬀect sizes
(Cohen’s d) were calculated to distinguish relevant
eﬀects from trivial but statistical signiﬁcant eﬀects.
Normality of the dependent variables (cognitive
functioning) was checked visually with histograms
and box plots and conﬁrmed if the test statistic W in
the Shapiro–Wilk test exceeded 0.90. Of the 13 depen-
dent variables, 11 were normally distributed. Due to
ceiling eﬀects, parameters for CPT accuracy and the
Hinting Task were not normally distributed. Since a
logarithmic transformation did not result in a normal
distribution, these scores were dichotomized into ‘af-
fected’ and ‘unaﬀected’ individuals. ‘Aﬀected’ for the
CPT accuracy (range 0–100%) was deﬁned as<100%
accurate responses (51.6% of total sample) and for the
Hinting Task (range 0–20) as a score <20 (57.8% of
total sample). Generalized estimating equation (GEE)
analyses were used to assess the eﬀect of the inde-
pendent variables on these two dichotomous out-
comes (Hanley et al. 2003). The GEE models were
analysed in addition to the random-eﬀect regression
models and built in the same way. To minimize the
risk of type I errors, the analysis yielding the most
conservative results for these two cognitive outcomes
was selected for the discussion. Analyses were per-
formed using SPSS 17.0 for Windows (SPSS Inc., USA).
Results
Characteristics of the study sample
The GROUP sample consisted of 1120 patients with
non-aﬀective psychotic disorder, 1057 siblings of these
patients and 590 unrelated controls. Subjects that had
not performed cognitive testing (n=42) and subjects
without a valid drug urine screening (n=255) were
excluded from the current study. We excluded seven
subjects with a negative urine screening because in-
formation on lifetime cannabis use was missing.
Analyses were performed on the remaining 2463 sub-
jects (956 patients, 953 unaﬀected siblings, 554 con-
trols). DSM-IV-TR diagnoses of the patients were as
follows: schizophrenia (DSM-IV 295.1/295.2/295.3/
295.6/295.9, n=681, 71.2%), schizoaﬀective disorder
(DSM-IV 295.7, n=111, 11.6%), other psychotic dis-
orders (DSM-IV 297/298, n=145, 15.2%) and psy-
chotic illness in the context of substance abuse or
somatic illness (n=8, 0.8%). A total of eleven patients
(1.2%) had a ﬁnal diagnosis of aﬀective psychosis al-
though fulﬁlling criteria for a clinical diagnosis of non-
aﬀective psychosis at study entry.
As presented in Table 1, control subjects were older
(30.2 years) than patients (27.3 years) and siblings (27.9
years). Males were overrepresented in the patient
group (76.4%) compared with siblings (45.4%) and
controls (45.5%). Parental educational degree and
subject educational degree were lowest in patients. Of
all subjects, 38.3% (n=943) had used cannabis in their
lifetime, and 10.5% (n=258) were current cannabis
users. Patients and siblings were more likely to be
current or lifetime cannabis users compared with
controls. Regarding the frequency of cannabis use over
the past year, patients and siblings were more likely to
be daily users compared with controls. Patients were
also more likely to be using nicotine or illicit sub-
stances compared with siblings and controls. Groups
did not diﬀer in the proportion of heavy alcohol users.
Table 2 shows that patients with current or lifetime
cannabis use were 2.4 years younger and more often
male compared with never-using patients. Current
and lifetime cannabis-using patients had lower func-
tioning on theGlobal Assessment of Functioning (GAF;
APA, 2000) disability scale (52.9 v. 58.3), higher PANSS
positive symptoms (14.6 v. 12.4), but similar PANSS
negative symptoms compared with patients who had
never used cannabis. In both groups around 85% of
patients received treatment with antipsychotics.
Cannabis recency
In the current user group (n=258), 59.4% were using
daily, 30.3% weekly, and 10.3% less than weekly. The
lifetime user group (n=943) consisted of 44.1% daily
users, 25.7%weekly users, and 30.2% less than weekly
users. The never-user group consisted of 1262 subjects.
The interaction term between status (patient, sibling,
control) and cannabis recency (current, lifetime, never)
was not statistically signiﬁcant for any of the cognitive
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variables and was therefore removed from the re-
gression models. Fig. 1c demonstrates that patients
performed worse than controls on all cognitive par-
ameters except RST reaction time, while siblings per-
formed intermediate to patients and controls on
selected tasks. Fig. 1 a demonstrates that, while taking
the main eﬀect of status into account, current cannabis
users performed signiﬁcantly worse compared with
never-users on the Word Learning Task immediate
recall (d=x0.20), WAIS-III digit-symbol coding
(d=x0.22) and WAIS-III arithmetic (d=x0.20). Life-
time cannabis users performed better than never-users
on WAIS-III information (d=+0.17), the Degraded
Facial Aﬀect Recognition task (d=+0.33) and the
Benton Face Recognition Task (d=+0.21). In addition,
current cannabis users performed signiﬁcantly better
than never-users on WAIS-III information (d=+0.19).
Repeating the analyses after changing the reference
category to current users yielded signiﬁcant diﬀer-
ences between current and lifetime users for the Digit-
Symbol Coding (d=+0.15, p<0.011) and for theWord
Learning Task immediate recall (d=+0.18, p<0.001),
the latter of which remained signiﬁcant after adjusting
for multiple comparisons.
GEE analyses conﬁrmed the mixed-model re-
gression results for the not normally distributed data.
For CPT accuracy, the proportion of ‘aﬀected’ in-
dividuals was not signiﬁcantly diﬀerent within cur-
rent (58.8%), lifetime (53.1%) and never-users (49.0%)
[Wald x2(2)=0.98, p=0.61]. Also for the Hinting Task,
the proportion of ‘aﬀected’ individuals was not sig-
niﬁcantly diﬀerent within current (64.0%), lifetime
Table 2. Demographic and clinical variables of patients with and without a lifetime history of cannabis use
Cannabis use (lifetime+
current) (n=632)
Never cannabis
use (n=324)
t (df)
or x2 (df) p
Mean age, years (S.D.) 26.5 (6.4) 28.9 (8.7) 4.9 (954) <0.001
Gender, % male 86.1 57.4 97.5 (1) <0.001
Education, % lowest (% highest) 15.2 (3.0) 6.8% (6.8) 34.1 (8) <0.001
Parental education, % lowest (% highest) 7.1 (19.0) 5.9% (17.0) 11.9 (8) N.S
Mean GAF disability (S.D.) 52.9 (16.0) 58.3 (15.5) 4.8 (919) <0.001
Mean PANSS positive scale (S.D.) 14.6 (6.7) 12.4 (5.7) x4.9 (930) <0.001
Mean PANSS negative scale (S.D.) 15.2 (6.6) 14.7 (6.4) x1.2 (930) N.S
Antipsychotic treatment, % yes 86.3 84.9 2.0 (2) N.S
df, Degrees of freedom; S.D., standard deviation ; N.S., non-signiﬁcant ; GAF, Global Assessment of Functioning ; PANSS,
Positive and Negative Syndrome Scale.
Table 1. Demographic variables of patients, siblings, and controls
Patients
(n=956)
Siblings
(n=953)
Controls
(n=554)
F (df) or x2
(df) p
Mean age, years (S.D.) 27.3 (7.4) 27.9 (8.3) 30.2 (10.5) 21.6 (2, 2459) <0.001
Gender, % male 76.4 45.4 45.5 229.0 (2) <0.001
Education, % lowest (% highest) 12.3 (4.3) 7.1 (12.0) 2.2 (9.4) 244.5 (16) <0.001
Parental education, % lowest (% highest) 6.7 (18.3) 5.1 (18.8) 4.3 (16.1) 35.22 (16) <0.004
Nicotine use, % 66.4 37.5 25.5 282.4 (2) <0.001
Heavy alcohol use, % 10.9 9.0 7.7 4.6 (2) N.S.
Other substance use, % 20.4 7.8 6.0 97.09 (2) <0.001
Cannabis recency (n=2463)
Current, % 16.3 7.9 4.9 60.16 (2) <0.001
Lifetime, % 49.8 33.4 26.9 93.82 (2) <0.001
Never, % 33.9 58.7 68.2 200.49 (2) <0.001
Cannabis frequency in the past year (n=612)
Daily, % 48.3 25.6 19.5 38.71 (2) <0.001
Weekly, % 26.6 28.3 30.5 0.57 (2) N.S.
Less, % 25.1 46.1 50.0 32.12 (2) <0.001
df, Degrees of freedom; S.D., standard deviation ; N.S., non-signiﬁcant.
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Fig. 1. (a) Main eﬀects of cannabis recency on cognitive functioning : - -’- -, current users ; –&–, lifetime users ; –m–, never-users.
Eﬀects that remained signiﬁcant after correction for multiple comparisons (p<0.005) in current/lifetime users compared with
never-users are circled. (b) Main eﬀects of cannabis frequency on cognitive functioning : –&–, daily ; - -’- -, weekly ; –m–,
monthly. (c) Main eﬀects of status on cognitive functioning : - -’;- -, patients ; –&–, siblings ; –m–, controls. WLT IR, Word
Learning Task immediate recall ; WLT RR, Word Learning Task retention rate ; RST RT, Response Shifting Task reaction time ;
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(60.0%) and never-users (54.8%) [Wald x2(2)=0.35,
p=0.84].
Cannabis frequency
The interaction term between status (patient, sibling,
control) and cannabis frequency (daily, weekly, less)
was not statistically signiﬁcant for any of the cognitive
variables and was therefore removed from the re-
gression models. In the resulting model, including
status, cannabis frequency and relevant confounders,
there was no signiﬁcant eﬀect of cannabis frequency
on any of the cognitive parameters (Fig. 1b). GEE
analyses conﬁrmed the mixed-model regression re-
sults for the not normally distributed data. For CPT
accuracy, the proportion of ‘aﬀected’ individuals was
not signiﬁcantly diﬀerent within daily (57.1%), weekly
(59.6%) and less frequent users (52.6%) [Wald
x2(2)=1.87, p=0.39]. For the Hinting Task, the pro-
portion of ‘aﬀected’ individuals was not signiﬁcantly
diﬀerent within daily (70.7%), weekly (60.5%) and less
frequent users (60.9%) [Wald x2(2)=1.74, p=0.42].
Status
Although not a primary aim of this study, the main
eﬀects of status on cognitive functioning are outlined
in Fig. 1c in order to facilitate interpretation of the re-
sults. The main eﬀects of cannabis (recency and
frequency) have been assessed in random-eﬀect re-
gression models together with the main eﬀect of status
and the interaction between cannabis and status. The
interaction terms were non-signiﬁcant and the main
eﬀects of cannabis and status on cognitive functioning
should thus be added. We illustrate this with an ex-
ample. On the Word Learning Test immediate recall,
patients scoredx0.95 S.D. from control mean (Fig. 1c).
Moreover, current cannabis users scored x0.2 S.D.
from never-users (Fig. 1a). Therefore, the mean score
of current cannabis-using patients liesx1.15 S.D. from
the mean score of never-using controls.
Discussion
The aim of this cross-sectional study was to investigate
how recency and frequency of cannabis use are associ-
ated with cognitive performance in patients with
non-aﬀective psychosis, their unaﬀected siblings and
control subjects. In line with our ﬁrst hypothesis,
current cannabis use was associated with worse per-
formance on immediate verbal learning, processing
speed and working memory, and this association did
not diﬀer between the three status groups. However,
against our expectations, an increasing frequency of
cannabis use over the past year was not associated
with worse cognitive performance. Our second
hypothesis was partly supported. While lifetime can-
nabis use was indeed associated with better perform-
ance on acquired knowledge, aﬀect recognition and
face identity recognition in patients, this association
also applied to unaﬀected siblings and controls. Eﬀect
sizes of these associations were in the small range,
which may explain why previous studies that in-
cluded smaller sample sizes have found contradictory
results (Coulston et al. 2007b). The interpretation of the
results is discussed here. As the comparison of cogni-
tive performance between patients, siblings and con-
trols (Fig. 1c) was not the primary aim of this study,
we refer to our baseline study on cognitive assessment
in GROUP for further interpretation of these results
( J. H. Meijer, C. J. P. Simons, P. J. Quee, K. Verweij,
GROUP Investigators, unpublished observations).
A negative association between cognitive function-
ing and current – but not lifetime – cannabis use is
likely to result from a residue of cannabinoids in the
central nervous system. Worse immediate verbal
learning in current cannabis users is in agreement with
other studies in patients with psychotic illness (Liraud
& Verdoux, 2002 ; Pencer & Addington, 2003 ; D’Souza
et al. 2005 ; Sevy et al. 2007; Jockers-Scherubl et al. 2007;
Coulston et al. 2007a ; Yu¨cel et al. 2010). Also in healthy
controls, immediate verbal learning is one of the most
consistently impaired cognitive functions after acute
cannabis administration, and, congruent with our re-
sults, this eﬀect appears to be transient after a 4-week
abstinence (Grant et al. 2003 ; Solowij & Michie, 2007).
In contrast with our ﬁnding of worse processing
speed in current users, the majority of studies in
schizophrenia patients reported either absent, or even
positive eﬀects of both current and lifetime cannabis
use on visual processing speed (Sevy et al. 2007 ;
Jockers-Scherubl et al. 2007 ; Coulston et al. 2007a ;
Schnell et al. 2009 ; DeRosse et al. 2010). Positive
associations in those studies might have been
driven by higher pre-morbid cognitive functioning in
cannabis-using patients (Fried et al. 2005 ; Schnell et al.
RST Acc, Response Shifting Task accuracy ; CPT RT, Continuous Performance Task-HQ reaction time ; CPT Acc, CPT-HQ
accuracy ; DS coding, Wechsler Adult Intelligence Scale-Third Edition (WAIS-III) digit-symbol coding ; Arithm, WAIS-III
arithmetic ; Inform, WAIS-III information ; Block, WAIS-III block design ; Aﬀect Rec, Degraded Facial Aﬀect Recognition total
score ; Face Rec, Benton Face Recognition ; Hinting, Hinting task ; F, test statistic from mixed-model regression analyses ; df,
degrees of freedom.
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2009). Our ﬁnding that current – but not lifetime –
cannabis users show worse processing speed is, how-
ever, in agreement with evidence from studies in
control subjects (Ehrenreich et al. 1999 ; Fried et al.
2005).
Similar to our ﬁndings, recent cannabis use in
schizophrenia patients has been associated with worse
working memory (Ringen et al. 2010), but absent or
positive associations have also been reported (Sevy
et al. 2007 ; Mata et al. 2008 ; Scholes & Martin-Iverson,
2010). Opposite ﬁndings may have resulted from dif-
fering samples sizes or the heterogeneity of working
memory measures that have been used. WAIS-III
arithmetic may be regarded as a relatively complex
measure of working memory, with split loadings
on processing speed and verbal comprehension
(Tellegen, 2003). Our ﬁndings are supported by
studies in control subjects that reported impaired
working memory following intravenous THC admin-
istration and cannabis smoking (Ilan et al. 2004 ;
Morrison et al. 2009), while lifetime cannabis use was
not associated with working memory impairments
(Scholes & Martin-Iverson, 2010).
Of those subjects who had used cannabis over the
past year, daily or weekly users did not perform sig-
niﬁcantly diﬀerent compared with less frequent users.
Although these ﬁndings seem counterintuitive, they
are corroborated by the literature in schizophrenia
patients (Rodriguez-Sanchez et al. 2010) and in healthy
subjects (Pope et al. 2002). Tolerance for the adverse
cognitive eﬀects of cannabis in more frequent users
might have accounted for the absence of a dose–
response relationship on cognitive functioning
(Ramaekers et al. 2009). Another explanation may be
that the subdivision of frequency into daily, weekly,
and less frequent use was not sensitive enough to de-
tect a dose–response relationship.
Our ﬁnding that lifetime cannabis use was not as-
sociated with worse cognitive functioning is in line
with a recent review that reported no convincing evi-
dence for sustained cognitive impairments in adult
abstinent cannabis users (Van Holst & Schilt, 2011). On
the other hand, both current and lifetime cannabis
users performed better than never-users on acquired
knowledge. Better acquired knowledge in current
users may reﬂect the fact that current users are also
lifetime users, since it is unlikely that they started
using cannabis in the past month. In addition, we
found that lifetime cannabis users performed better
than never-users on tasks of facial aﬀect recognition
and face identity recognition. Research on the associ-
ation between cannabis use and facial aﬀect and
identity processing is sparse in both patients and
controls. One study reported that patients who had
used cannabis prior to psychosis onset showed a
relative sparing of face identity recognition at 10- to
12-year follow-up, but this diﬀerence was lost after
co-varying for age at psychosis onset (Stirling et al.
2005). In non-psychotic polysubstance users, cannabis
use was not associated with quality of facial aﬀect
recognition, but this association might have been con-
founded by diﬀering eﬀects of other substances
(Fernandez-Serrano et al. 2011).
A positive association between lifetime cannabis
use and cognitive functioning may seem counter-
intuitive given the detrimental eﬀects in acute admin-
istration studies (D’Souza et al. 2005 ; Morrison et al.
2009). It has been suggested that substance-using
patients might need better cognitive and social skills in
order to maintain an illicit substance use (Joyal et al.
2003 ; Potvin et al. 2005), but in the Netherlands can-
nabis is not illegal and can be purchased with lesser
restrictions. In other words, subjects do not need
superior social functioning to obtain cannabis.
Moreover, in a recent meta-analysis, superior neuro-
psychological functioning in cannabis-using schizo-
phrenia patients was largely driven by the inclusion
of lifetime users, rather than current or recent users
(Yu¨cel et al. 2010). Our results support the hypothesis
that cannabis-using patients might constitute a sub-
group of patients that is intrinsically less vulnerable
for schizophrenia than patients who have never used
cannabis (Zubin & Spring 1977; Mueser et al. 1998).
Once triggered, a drug-induced non-aﬀective psy-
chotic illness may be indistinguishable from psychosis
due to a suﬃcient amount of biological vulnerability,
although pre-morbid functioning and cognitive resili-
ence may be better.
This developmental model has been supported by
various studies that investigated the order in which
cannabis use and psychosis occur. Three studies found
that cognitive functioning was speciﬁcally preserved
in patients who had started cannabis consumption
before disease onset (Stirling et al. 2005 ; Rodriguez-
Sanchez et al. 2010) or before the age of 17 years
( Jockers-Scherubl et al. 2007). These studies suggest
that it is not the cognitive eﬀects of cannabis per se, but
the contribution of cannabis to disease onset that ex-
plains better cognitive functioning in cannabis-using
patients. Second, evidence from follow-up studies
suggests that acutely admitted psychotic patients
using cannabis have a higher recovery potential for
both cognitive and clinical parameters, especially after
cessation of cannabis use (Loberg & Hugdahl, 2009 ;
Gonza´lez-Pinto et al. 2011). Third, studies focusing on
neurodevelopmental and genetic factors have added
credibility to the vulnerability hypothesis. Cannabis
use before psychosis onset has been associated with
fewer neurological soft signs after transition to psy-
chosis, which is thought to reﬂect a lower genetic
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loading in those patients (Bersani et al. 2002 ; Stirling
et al. 2005 ; Ruiz-Veguilla et al. 2009).
It should, however, be stressed that lifetime canna-
bis use in our patients was associated with a lower
educational degree. In healthy individuals adolescent
cannabis use is known to increase the risk of poor
school performance, and in particular early school
leaving (Lynskey & Hall, 2000). Cannabis use is also
known to make an impact negatively upon later em-
ployment in control subjects (Fergusson & Boden,
2008), and the impact may be even more severe in a
cognitively vulnerable population of psychotic
patients.
Other than in patients with psychosis and healthy
controls, evidence on the association between cannabis
use and cognition in genetic high-risk subjects is
sparse. In agreement with our results, Henquet et al.
(2006) found that acute THC administration in unaf-
fected siblings and control subjects was associated
with a cognitive decline in domains of verbal memory
and processing speed. In addition, preliminary evi-
dence suggested that sensitivity to the cognitive
eﬀects of THC might be moderated by a functional
polymorphism in the catechol-O-methyltransferase
(COMT) gene that is also known to moderate the risk
of developing psychosis in reaction to cannabis use
(Henquet et al. 2006). The present study is to our
knowledge the ﬁrst observational study to assess the
relationship between daily-life cannabis use and cog-
nitive functioning in genetic high-risk subjects.
Finally, a signiﬁcant interaction term would have
indicated that the association between cannabis use
and cognitive functioning was diﬀerent between pa-
tients, siblings and controls, but this was not the case.
Although there have been suggestions of an increased
vulnerability to the cognitive adverse eﬀects of acute
THC administration in patients and their siblings
(D’Souza et al. 2005 ; Henquet et al. 2006), we did not
replicate this ﬁnding. A ﬁrst explanation might be that
such an interaction eﬀect is restricted to the ﬁrst hours
following acute intoxication of cannabis and not ap-
plicable to eﬀects resulting from a residue of cannabi-
noids in the brain. A second diﬀerence in study
methodologies is the psychoactive substance of use.
While previous studies found an interaction eﬀect on
cognitive functioning between psychosis vulnerability
and THC, we assessed associations with current,
daily-life cannabis use. Contrary to cannabis, THC is a
synthetic preparation that is devoid of cannabidiol,
which is a potential inhibitor of pharmacological ef-
fects of CB1 agonists (Pertwee, 2008). Further research
needs to clarify the association between individual
cannabis components and cognitive functioning in
individuals with psychosis and their unaﬀected re-
latives. Despite the absence of an interaction eﬀect, our
ﬁndings do not imply that campaigns to discourage
cannabis use are without merit. The adverse eﬀects of
cannabis use on psychotic symptomatology are well
acknowledged in both patients (Linszen et al. 1994 ;
Macleod, 2007 ; Castle, 2008) and individuals at genetic
risk for psychosis [Caspi et al. 2005 ; GROUP
Investigators, 2011].
The following limitations should be taken into ac-
count. First, the cross-sectional design restricts the
drawing of causal inferences between cannabis use
and cognitive functioning. Second, we cannot fully
exclude the possibility that some of the current users
in our study were tested within less than 24 h after
cannabis consumption so that the eﬀects measured
were those of acute intoxication. However, instructing
frequent users to abstain from cannabis use before
testing could have a negative eﬀect on cognition as
well, similar to those of acute intoxication (Pope et al.
2002). Third, it should be acknowledged that the
amount of cannabis use in the lifetime user group
could have been highly variable (ranging from ﬁve
times to>100 times) which may have led to a dilution
of cannabis eﬀects. Hence, we cannot exclude that
higher quantities of lifetime cannabis use may have
had a signiﬁcant harmful eﬀect on cognitive function-
ing. On the other hand, using ﬁve times or more as a
cut-oﬀ for lifetime use is likely to select out most of the
users who have experimented with cannabis without
proceeding into continued use. This is illustrated by
Perkonigg et al. (2008), who refer to the use of cannabis
of ﬁve times or more as ‘repeated use’. Their study on
the long-term natural course of cannabis use in a
community sample of adolescents revealed that these
repeated users were almost three times more likely to
report cannabis use at 10-year follow-up (odds ratio
2.8, 95% conﬁdence interval 1.6–4.7) compared with
those who had used cannabis fewer than ﬁve times.
The strength of this study is that, due to the com-
prehensive database of the GROUP study, we were
able to address recommendations that have been
made in prior studies (Coulston et al. 2007b ; Yu¨cel
et al. 2010), such as investigating both recency and
frequency of cannabis use, the inclusion of a cannabis-
using control group, biological validation of self-
report cannabis measures by urine drug screening, the
assessment of a broad range of cognitive measures,
and controlling for a range of possible confounders.
Furthermore, the current study expanded on existing
studies by the inclusion of unaﬀected siblings, so that
we were able to draw conclusions on the association
between cannabis and cognition in people at genetic
high risk for psychosis.
Our ﬁndings implicate that cannabis use in patients,
siblings and controls is associated with diﬀerences in
cognitive performance, depending on the recency of
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use. Current cannabis users perform worse on tasks of
short-term memory and processing speed which may
reﬂect residual eﬀects. Lifetime cannabis users per-
form better on social cognition and acquired knowl-
edge, which is more likely to result from lower
biological vulnerability and higher pre-morbid func-
tioning rather than an eﬀect of cannabis itself. This
discrepancy between potential and actual perform-
ance is clinically relevant for those patients whose
cannabis use might complicate a potentially less se-
vere course of psychosis. Studies with a longitudinal,
prospective design may optimally address this issue,
as it permits within-subject comparisons of cognitive
performance before initiation and after cessation of
cannabis use.
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